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Assembly factorThe mammalian Complex III (CIII) assembly process is yet to be completely understood. There is still a lack in un-
derstanding of how the structural subunits are put together andwhich additional factors are involved. Here we de-
scribe the identiﬁcation and characterization of LYRM7, a humanprotein displaying high sequence homology to the
Saccharomyces cerevisiae protein Mzm1, which was recently shown as an assembly factor for Rieske Fe–S protein
incorporation into the yeast cytochrome bc1 complex. We conclude that human LYRM7, which we propose to be
renamed MZM1L (MZM1-like), works as a human Rieske Fe–S protein (UQCRFS1) chaperone, binding to this
subunit within the mitochondrial matrix and stabilizing it prior to its translocation and insertion into the late CIII
dimeric intermediate within the mitochondrial inner membrane. Thus, LYRM7/MZM1L is a novel human CIII
assembly factor involved in the UQCRFS1 insertion step, which enables formation of the mature and functional
CIII enzyme.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Complex III (CIII) or ubiquinol:cytochrome c oxidoreductase (E.C.
1.10.2.2; the cytochrome bc1 complex) is the central enzyme of the
mitochondrial respiratory chain. It receives electrons from Coenzyme Q,
which is reduced mainly by Complex I through NADH-linked substrates
and by Complex II through FADH2-linked substrates. CIII then reduces
cytochrome c,which transfers the electrons to Complex IV, wheremolec-
ular oxygen is reduced towater. The oxidation and reduction reactions of
CIII are coupled to proton translocation from themitochondrial matrix to
the intermembrane space by the so-called Q cycle [1], contributing to the
membrane potential necessary for ATP synthesis.
Mammalian CIII possesses a symmetrical dimeric structure in which
each “monomer” is composed of 11 different subunits [2,3], three of
which are the catalytic subunits: MT-CYB (cytochrome b, the only
mtDNA-encoded subunit), CYC1 (cytochrome c1) and UQCRFS1 (Rieske
Fe–S protein).
The CIII assembly process has mainly been studied by using the
yeast S. cerevisiae as a model, taking advantage of this facultative an-
aerobic organism and its ability to survive on fermentative substratesTraslacional IACS, Hospital
0009 Zaragoza, Spain. Tel.: +34
(E. Fernández-Vizarra).
emistry, College of Charleston,
rights reserved.when its CIII is non-functional. By analyzing the composition of the
sub-complexes present in different yeast deletion strains, a model in-
volving a multi-step process and the formation of different assembly
intermediates has been described (reviewed in [4]). In addition, several
yeast proteins are known to assist the process by acting in different parts
of the assembly pathway [4]. By means of putting all subunits together
except the Rieske Fe–S protein (Rip1) and the smallest subunit Qcr10, a
considerably stable non-functional “late core” subcomplex, or pre-CIII2
intermediate, is formed. The assembly of the complex is completed
when Rip1 is inserted in the last step, followed by Qcr10 [5].
As for all nuclear-encoded mitochondrial proteins, yeast Rip1 is syn-
thesized in the cytoplasm and then imported inside mitochondria. Rip1
is transported completely into the matrix to receive the 2Fe–2S cluster
cofactor necessary for its function, and the protein is proteolytically
processed in two steps [6]. Differing from yeast, UQCRFS1 in mammals
is processed in a single step, and what was originally the pre-sequence
is retained as a structural subunit [7]. Translocation of the Rieske Fe–S
protein from thematrix to themitochondrial innermembrane for its in-
sertion into CIII is mediated by the AAA-ATPase Bcs1 [8]. The human
ortholog, BCS1L, seems to perform the same function as in yeast, as dem-
onstrated by analysis of CIII assembly in patients carrying deleterious
mutations in the BCS1L gene [9–11], in which the pre-CIII2 late interme-
diate lacking UQCRFS1 is accumulated.
Recently, a yeast protein involved in this last Rip1 insertion step has
been described [12,13]. Lack of this protein, Mzm1, is associated with a
defect in CIII maturation and reduced CIII activity, as well as very low
Rip1 steady-state levels. Furthermore, Mzm1 was demonstrated to
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venting its proteolytic degradation or its aggregation under conditions
in which Rip1 could not be incorporated into CIII [13,14].
Here, we report the ﬁnding and functional characterization of
LYRM7, a human protein showing high amino acid sequence homology
to the yeast Mzm1. Our results point out that LYRM7 is the MZM1-like
(MZM1L) protein, i.e., acting as a Rieske Fe–S protein chaperone in
human cells that binds to the subunit within the matrix in a step prior
to its insertion into the late pre-CIII2 intermediate. Thus, LYRM7/
MZM1L appears to be an assembly factor for the late stage of CIII assem-
bly in humans.
2. Materials and methods
2.1. Cell lines and cell culture
Human primary and immortalized skin ﬁbroblasts, HEK 293T and
HeLa cells were grown at 37 °C in a 5% CO2 atmosphere in high-glucose
plus glutamine and sodium pyruvate DMEM medium (Gibco-Life
Technologies) supplemented with 10% fetal bovine serum (FBS from
PAN-Biotech), 1× penicillin–streptomycin (Gibco-Life Technologies)
and 50 μg/ml Uridine (in the case of CIII-deﬁcient cell lines). For the
puromycin-resistant cells, a ﬁnal concentration of 1 μg/ml in themedium
was used. Mouse L929 ﬁbroblasts were cultured in the same conditions
except for the ﬁnal FBS concentration, which was 5%.
Primary human skin ﬁbroblasts were immortalized by lentiviral
transduction using the pLox-Ttag-ires-TK vector (Tronolab) [15].
2.2. Yeast growth assay
S. cerevisiae expression vectors were constructed to bear the coding
sequences for: 1) the human gene LYRM7 (transcript 1; see Section 2.3),
followed by 6 histidine repeats and a single Myc tag, 2) the yeast gene
MZM1, followed by a single Myc tag and 6 histidine repeats, and 3) the
yeast gene SDH6, followed by 6 histidine repeats and a single Myc tag.
These coding sequences were cloned into a common high-copy-number
pRS426 plasmid bearing a URA3 selection marker and expressed under
the control of the yeastMET25 promoter and CYC1 terminator sequences
[16]. These plasmids aswell as an empty vector controlwere transformed
into wild-type and Δmzm1 deletion yeast strains of the BY4741 ge-
netic background via a variation of the lithium acetate procedure
[17]. Transformed cells were grown on selective plates containing
Brent supplement mixture lacking uracil (Sunrise Science Products,
San Diego, CA) plus 2% glucose, and colonies were inoculated into
4-ml cultures of the samemedia, grown overnight, and spotted onto se-
lective plates containing either 2% glucose or 2% glycerol/2% lactate at
equivalent optical densities (at 600 nm) in a 10-fold serial dilution.
Plates were incubated at 30 °C or 37 °C and photographed after ~48 h
(glucose) and ~144 h (glycerol-lactate) of growth.
2.3. LYRM7 constructs
cDNAwasobtainedbyusing theGoScript reverse transcription system
(Promega), using total RNA extracted from cultured cells with TRIzol re-
agent (Invitrogen). PCR products were produced using cDNA as the tem-
plate with speciﬁc primers: hLYRM7-MluI-Fw: 5′-CTTTACGCGTCAGTCTT
TGATTGGTTGCTG-3′ and hLYRM7-SalI-Rv: 5′-CCCCGTCGACCTTGTTGTA
TTCTAGAAAAC-3′; mLyrm7-MluI-Fw: 5′-CTTTACGCGTGGGGAGCCATGG
GTCAG-3′ and mLyrm7-SalI-Rv: 5′-CCCTGTCGACAGAGATGGGTTTATCCT
GG-3′. The obtained PCR productswere cloned into the pCR2.1 TA cloning
system (Invitrogen). Sequence checked clones containing the two insert
variants (LYRM7-001 and LYRM7-003) were used as templates for the
ampliﬁcation to add the HA tag at the C-terminus of the putative protein
products, using the same hLYRM7-MluI-Fw primer and hLYRM7-001-
HA-SalI-Rv: 5′-CCCGTCGACTCAAGCGTAATCTGGAACATCGTATGGGTATT
GCTTCTGAGTTGGTGCATC-3′ or hLYRM7-003-HA-SalI-Rv: 5′-CCCGTCGACTCAAGCGTAATCTGGAACATCGTATGGGTACAAGAAGGTCTTTCCTAGGG-3′.
The PCR products were cloned into the pCR2.1 TA cloning system
(Invitrogen). Inserts with the correct sequences were subsequently
cloned into a lentiviral expression vector derived from pWPXLd
(Tronolab), in which the GFP sequencewas substituted by a puromy-
cin resistance cassette (pWPXLd-ires-PuroR).
2.4. Lentiviral transduction
Lentiviral particles containing the LYRM7-001-HA/pWPXLd-ires-
PuroR, LYRM7-003-HA/pWPXLd-ires-PuroR or the empty pWPXLd-ires-
PuroR vectors were generated in HEK 293T packaging cells, and HeLa
cells were transduced with the former as described [18]. Twenty-four
hours after transduction, cells were selected for puromycin resistance
(Section 2.1).
2.5. Isolation and subfractionation of mitochondria
Mitochondrial preparations from transducedHeLa cellswere obtained
as described [19]. For subfractionation of mitochondria, to separate the
soluble and membranous fractions, freshly isolated mitochondria were
sonicated three times and then centrifuged at 100,000 ×g for 30 minutes
at 4 °C to separate the supernatant containing the soluble proteins and
the membrane pellet [20]. To split the peripherally bound from the inte-
gral membrane proteins in the pellet from the previous step, the samples
were resuspended in a buffer containing 0.1 M Na2CO3, pH 10.5, 0.25 M
sucrose and 0.2 mM EDTA; incubated for 30 min on ice and then
centrifuged at 100,000 ×g for 30 minutes at 4 °C, to separate the pellet
from the supernatant [21].
2.6. Immunoprecipitation
Approximately 500 μg of mitochondrial protein isolated from HeLa
cells, either transduced with the empty pWPXLd-ires-PuroR vector or
overexpressing LYRM7-001-HA (MZM1L-HA), were lysed in PBS with
140 mM NaCl, 1% n-Dodecyl β-D-maltoside (DDM) and protease
inhibitor cocktail (Sigma), during 30 minutes on ice. The lysate was
cleared by centrifugation at 20,000 ×g for 30 minutes and divided
into three aliquots, which were each incubated with 1.5 μg of high
afﬁnity anti-HA antibody (Roche), anti-Rieske protein antibody (Molec-
ular Probes-Invitrogen) or mouse serum IgGs (Sigma) for 5 hours at
4 °C. Immunoprecipitationwas achieved by adding pre-washed Protein
G-Sepharose 4B beads (Invitrogen) and incubating an additional
2 hours at 4 °C. The co-immunoprecipitates were washed three times
in astringent conditions (PBSwith 400 mMNaCl, 0.1% DDMand protease
inhibitor cocktail) and once in low salt conditions (PBS with 140 mM
NaCl, 0.1% DDM and protease inhibitor cocktail). Proteins were ﬁnally
eluted from the beads with 2× Laemmli Sample Buffer and heated at
95 °C for 5 minutes.
2.7. Protein electrophoresis, Western blot and immunodetection
Total protein extracts from cultured cells or fractions were resolved
under denaturing conditions using 16.5% polyacrylamide Tricine-
SDS-PAGE [22] or standard 15% polyacrylamide SDS-PAGE.
Blue-Native Gel Electrophoresis (BNGE) was performed using
mitoplast samples prepared by lysing cells in the presence of digitonin,
followed by a ﬁnal solubilization with 1% DDM as described [23]. The
complexes were resolved in 5–13% gradient polyacrylamide native
gels [24]. For the second denaturing dimension, 16.5% polyacrylamide
Tricine-SDS-PAGE preceded by a 10% polyacrylamide stacking gel was
used [9].
The gels were electroblotted to PVDF membranes, and the im-
mobilized proteins were immunodetected using speciﬁc antibodies as
indicated in each case. Anti-Core 1 (CIII subunit 1), anti-Core 2 (CIII
subunit 2), anti-COI (Complex IV subunit I) and Mitoproﬁle (Total
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anti-Rieske protein was from Molecular Probes-Invitrogen, anti-BCS1L
was from Proteintech Group, High Afﬁnity anti-HA was from Roche
and anti-Actin and anti-LYRM7 were from Sigma.
2.8. Respiratory chain enzymatic activity measurements
For the biochemical kinetic reaction assays, digitonin-solubilized cell
samples were used [25]. Individual CIII (decylubiquinol:cytochrome c
reductase), CIV (cytochrome c oxidase) and citrate synthase (CS) activi-
ties were measured as described [26], with slight modiﬁcations. The re-
actions were performed in 96-well plates in a ﬁnal volume of 200 μl and
measured in a Synergy HT Multi-Mode Microplate Reader (BioTek
Instruments).
2.9. Statistical analyses
First, analysis of variance (ANOVA)was used to test the difference be-
tween the mean values of the CIII and CIV activity measurements in the
different cell lines, normalized by citrate synthase. Secondly, the groups
were compared pair-wise using the Post-Hoc LSD test. p Valuesb0.05
were considered signiﬁcant. The statistical analyses were performed
using the SPSS 16.0 software for Windows.
2.10. Internet resources
National Center for Biotechnology Information: http://www.ncbi.
nlm.nih.gov/guide/
Ensembl Genome Browser: http://www.ensembl.org/index.html
Protein Knowledgebase (UniProtKB): http://www.uniprot.org/
ClustalW2 Multiple Sequence Alignment: http://www.ebi.ac.uk/
Tools/msa/clustalw2/
Human MitoCarta: http://www.broadinstitute.org/pubs/MitoCarta/
human.mitocarta.html
Mouse MitoCarta: http://www.broadinstitute.org/pubs/MitoCarta/
mouse.mitocarta.html
ExPASy compute pI/Mw tool: http://web.expasy.org/compute_pi/
3. Results
3.1. Identiﬁcation of the Mzm1 human and mouse orthologs
Performing a protein BLAST analysis using the Mzm1p amino acid
sequence (NCBI Protein Reference Sequence ID: NP_010781) resulted in
the identiﬁcation of the LYR motif containing 7 or human LYRM7
(NCBI Protein ID: NP_859056) and mouse Lyrm7 (NCBI Protein ID:
NP_083603) proteins as sequence homologs (Fig. 1A). The coding se-
quence for both species' proteins was ampliﬁed from cDNA using spe-
ciﬁc primers upstream of the initiation codon and downstream of the
stop codon (see Section 2.3). After screening 20 bacterial colonies
transformedwith each of the cloned PCR products, two different inserts
were detected in those ampliﬁed from human cDNA from either prima-
ry skin ﬁbroblasts or HEK 293T cells. Of the three predicted transcripts
for the human chromosome 5 gene listed in the Ensembl data base
(Ensembl Gene ID: ENSG00000186687), which should be ampliﬁed
with the primers used, we were able to obtain those corresponding to
transcript 1 (LYRM7-001; Ensembl Transcript ID: ENST00000379380)
and transcript 3 (LYRM7-003; Ensembl Transcript ID: ENST00000507
584). Transcript 1 encodes a 104 amino acid polypeptide, which is the
protein expected to be the Mzm1 human ortholog, while transcript 3
is a splicing variantwhere exon 4 is missing and is predicted to produce
a 63 amino acid protein. In the case of the mouse samples from cultured
L929 cells, we were able to amplify only one cDNA, corresponding to
the Lyrm7-005 transcript (Ensembl Transcript ID: ENSMUST00000
144164) of the mouse chromosome 11 gene (Ensemble Gene ID:ENSMUSG00000020268) encoding the 104 amino acid Mzm1 mouse
homolog.
3.2. Respiratory growth in Δmzm1 yeast strain is restored by LYRM7
Yeast strains lacking Mzm1 (Δmzm1) show defective growth on
non-fermentable carbon sources due to a defect in respiration linked to
a CIII deﬁciency, which is much more marked at 37 °C [12,13]. Some
human proteins involved in mitochondrial respiratory chain bio-
genesis, which are yeast factor functional homologs, are capable of
complementing respiratory defects in S. cerevisiae when the H. sapiens
allele is introduced in the deletion mutant yeast cells. This is the case,
for example, for the CIII assembly factor BCS1L [9,27].
To test for any such complementation in the case of LYRM7, the
human allele encoding the 104 amino acid LYRM7-001 was introduced
in the Δmzm1 cells. As can be seen in Fig. 1B, human LYRM7 restored
the ability of the mutant yeast strain to grow on non-fermentable
media at 37 °C, as did transformation with the yeast MZM1. Another
yeast protein included in the LYR motif family, SDH6 (human ortholog
SDHAF1), failed to restore the growth in Δmzm1 cells. Therefore, the
capacity of human LYRM7 to complement for the yeast respiration-
dependent growth defect induced by the lack of Mzm1 suggested that
the human protein not only shows a high sequence homology but that
it could also function in a similar manner as yeast Mzm1.
3.3. Overexpression of LYRM7/MZM1L in human cells produces a change in
the UQCRFS1 submitochondrial distribution and impairs CIII maturation
The HA tagged versions of LYRM7-001 and LYRM7-003 were over-
expressed in HeLa cells by lentiviral transduction. Western blot analyses
of total protein extracts from cells transduced with the empty vector
and with both LYRM7 constructs showed that only in the case of tran-
script 1, a protein product was detected using an anti-HA antibody
(Fig. 2A), even though LYRM7-003-HA was stably expressed at the
mRNA level (Fig. 2B).
Cells overexpressing LYRM7-001-HA, which will be referred to as
MZM1L-HA fromnowon, contain similar steady-state levels of UQCRFS1
(Rieske Fe–S protein) and other CIII subunits compared to the cells
transducedwith the empty vector or with the LYRM7-003-HA construct
(Fig. 2A).
LYRM7 is included in the mitochondrial proteome compendium
MitoCarta [28]. By cell subfractionation we aimed to conﬁrm this sub-
cellular localization and determine inwhichmitochondrial fraction, sol-
uble or membranous, it was found. In SDS-polyacrylamide gels, LYRM7
was detected in mitochondrial fractions when visualized by either
anti-LYRM7 or anti-HA immunoreactivity. In the cells overexpressing
LYRM7/MZM1L-HA, two bands appeared when using the speciﬁc
anti-LYRM7 antibody, the one corresponding to the endogenous protein
at the expected size of around 12 kDa (theoreticalmass: 11,955 Da) and
the other one migrating a little slower consistent with the HA tagged
protein theoreticalmass of 13,039 Da (Fig. 2A andC). In addition, anoth-
er band appeared to react with the anti-HA antibody located close to the
37 kDa molecular mass band (Figs. 2C, 5 and 6). The endogenous
LYRM7/MZM1L and the tagged MZM1L-HA showed the same subcellu-
lar and submitochondrial distribution in the different tested fractions
(Fig. 2C). Thus, both were detected mainly in the soluble mitochondrial
fraction (lanes 4 and 11) where the mitochondrial matrix marker SOD2
was present, concordantwith thematrix submitochondrial localization of
Mzm1 in yeast [12]. However, a fraction of LYRM7/MZM1L was associat-
ed with themitochondrial membranes (Fig. 2C, lanes 5 and 12) although
mostly peripherally, because considerable amounts were extracted from
the membrane pellet by sodium carbonate treatment (Fig. 2C, lanes 6
and 13).
HeLa cells overexpressingMZM1L-HAwere found to contain elevated
levels of UQCRFS1 in the mitochondrial soluble fraction (lane 11) than in
the membrane pellet (lane 12) in contrast to cells transduced with the
Fig. 1. LYRM7 as the yeast Mzm1p ortholog. A) Protein sequence alignment (ClustalW) of the yeast Mzm1 and human and mouse LYRM7, highlighting their high homology. The
human protein displays 29% identity and 46% homology with the yeast protein. B) Growth assay of a yeast strain lacking endogenous Mzm1 and expressing exogenous human
MZM1L. Wild-type (WT) and deletion mutant (Δmzm1) yeast over-expressing plasmid-born yeast MZM1, human LYRM7 (MZM1L), yeast SDH6 (an LYR protein with no known
role in CIII assembly), or a vector control were spotted onto solid media plates at equivalent cell densities and serially diluted 10-fold four times. Plates were incubated at 30 °C,
a condition under which yeast show no growth phenotype in the absence of endogenous Mzm1 protein, and at 37 °C, a stress condition under which growth in the absence of
Mzm1 is severely retarded.
Fig. 2. Characterization of the tagged LYRM7 constructs: expression and localization of the protein product. A) SDS-PAGE andWestern Blot of 3 different total protein amounts (10, 20 and
30 μg) extracted fromHeLa cells transducedwith the pWPXLd-ires-PuroR empty vector and the LYRM7-003-HA/pWPXLd-ires-PuroR and LYRM7-001-HA/pWPXLd-ires-PuroR constructs.
The blots were immunodetectedwith the indicated antibodies. B) PCR products ampliﬁed from cDNA, whichwas obtained from total RNA extracted fromHeLa cells thatwere transduced
with the pWPXLd-ires-PuroR empty vector and the LYRM7-001-HA/pWPXLd-ires-PuroR and LYRM7-003-HA/pWPXLd-ires-PuroR constructs, using the hLYRM7-MluI-Fw primer and an
oligonucleotide recognizing the HA sequence included at the end of each insert (5′-CAAGCGTAATCTGGAACATCG-3′). The ampliﬁcation products showed the expected sizes for
LYRM7-001-HA (416 bp) and for LYRM7-003-HA (300 bp). C) SDS-PAGE, Western blot and immunodetection of proteins in different cellular fractions from HeLa cells transduced
with the pWPXLd-ires-PuroR empty vector and the LYRM7-001-HA/pWPXLd-ires-PuroR (MZM1L-HA): Total cell homogenate (Total hom.), post-mitochondrial supernatant (Post-mt),
isolated mitochondria (Mitos), soluble mitochondrial subfraction (Sol. mt fract.), mitochondrial membrane fraction (Mt memb. fract.), and the soluble (Sol. CO32-) and insoluble (Pellet
CO32-) fractions obtained after sodium carbonate treatment of the mitochondrial membrane fraction. The blots were immunodetected with the indicated speciﬁc antibodies. SOD2 and
MT-CO1 were detected as markers for the mitochondrial matrix (soluble protein) and the mitochondrial membranes (inner membrane integral protein), respectively.
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was in the soluble fraction (lane 4) and most of it was in the insoluble
membrane pellet (lane 5 in Fig. 2C).
The presence of MZM1L-HA in amacromolecular complex was tested
by BNGE. The overexpressed tagged protein was present in a lowmolec-
ular weight complex of less than 100 kDa, migrating to the lowest part of
the native polyacrylamide gradient gel (Figs. 3A and 5A).
High levels of MZM1L-HA overexpression led to a decrease in the
amount of UQCRFS1 associated with CIII2. The signal corresponding to
UQCRFS1 was lower in MZM1L-HA cells compared to cells containing
the empty vector with a marked diminution in the abundance of the
UQCRFS1-containing CIII2+CIV supercomplex. In fact, the amount of
UQCRFS1 detected in the CIII2 and CIII2+CIV bands was inversely pro-
portional to the MZM1L-HA level, as seen in the cells infected with de-
creasing amounts of viral particles (Fig. 3A). On the other hand, the
amount of detected UQCRC2 (Core2 subunit) was comparable in all
the samples. In the sampleswhere Rieske Fe–S protein insertionwas re-
duced, there was an accumulation of the late core pre-CIII2, either alone
or in association with CIV. These species lacking UQCRFS1 appeared to
co-migrate in the Blue-Native gels with the corresponding fully assem-
bled complexes containing UQCRFS1. This co-migration is indicated in
Fig. 3A, where anti-Core2 detects both the UQCRFS1-less CIII2 and the
holo-CIII2 with or without CIV (pre-CIII2+CIII2+CIV and pre-CIII2+Fig. 3. Complex III assembly and activity in the transduced cells. A) First dimension (1D) BN
empty vector and with the MZM1L-HA construct. Samples are shown from two different e
transduce the cells, and Experiment 2, where different proportions of the total virus titrat
MZM1L-HA expression levels. Antibodies against subunits UQCRC2 (Core 2) and UQCRFS
MZM1L-HA, and CIV was detected using anti-COI. B) Denaturing second dimension analysi
with the lentiviral vector expressing MZM1L-HA (right). Proteins in the blots were detecteCIII2, respectively). This situation resembled what is observed when
the reduced incorporation of UQCRFS1 occurs due to mutations in
BCS1L [9]. In addition, stronger signals corresponding to UQCRC1 and
UQCRC2-containing subcomplexes, appeared in the highly expressing
MZM1L-HA transduced lines (Fig. 3B), indicating either a decreased sta-
bility or an impaired CIII assembly in these samples. Furthermore, in the
cells expressing high amounts of MZM1L-HA (100%, 50% and 25% of the
virus titration) an anomalous band migrating between CIII2+CIV and
CIII2 appeared in the immunodetection with the anti-Core 2 antibody
(Fig. 3A). This intermediate band (sub-CIII2+CIV) seemed to represent
the association of a partially assembled CIII with CIV, as it contains
UQCRC1, UQCRC2 andMT-CO1 (Fig. 3B), and its emergence could be as-
sociatedwith defective UQCRFS1 incorporation, as it was also evident in
BCS1L-mutated patient ﬁbroblasts [9].
Because UQCRFS1 is the last catalytic subunit to be incorporated into
CIII in the assembly pathway, if it is not properly inserted, the complex
cannot be functional. In accordwith observations from the BNGE,West-
ern blot and immunodetection analyses, CIII activity was reduced in the
cell lines where theMZM1L-HA expressionwas higher (Fig. 4A). On the
other hand, the pair-wise comparison of the measurements in the cells
infected with 6.25% of the total virus titration showed a statistically sig-
niﬁcant elevation in CIII activity with respect to the other cell lines gen-
erated using increasing virus concentrations (indicated in Fig. 4A). CIIIGE and immunoblot analyses of samples prepared from HeLa cells transduced with the
xperiments: Experiment 1, in which all the generated lentiviral particles were used to
ion (as indicated in the ﬁgure) were used to infect the cells, in order to modulate the
1 (Rieske protein) were used to evaluate CIII assembly. Anti-HA was used to detect
s after the 1D BNGE of transduced HeLa cells with the empty control vector (left) and
d using the indicated speciﬁc antibodies.
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duction with 12.5% of the total virus titration. Therefore, lower expres-
sion levels of the exogenous tagged polypeptide may contribute to the
endogenous protein function, helping in the stabilization/incorporation
of UQCRFS1 into the pre-CIII2 intermediate.
3.4. MZM1L and UQCRFS1 physically interact
Denaturing 2D analyses after a ﬁrst BNGE dimension clearly showed
the accumulation of the UQCRFS1 signal in positions corresponding to
low molecular weight complexes (Fig. 5A), which was more intense in
the samples in which MZM1L-HA was overexpressed (Figs. 3B and 5A).
The signals corresponding to the anti-HA antibody were also visualized
in these low molecular weight positions in the ﬁrst dimension, whichFig. 4. Complex III (A) and Complex IV (B) enzymatic activities normalized to the Citrate Sy
transduced HeLa cell lines. In experiment 2 cells were transduced with varying proportions (
four independent experiments (n=4)±SD. One way ANOVA analysis indicated statisticall
ences were found in CIV/CS activities (p=0.655). Asterisks indicate statistically signiﬁcant
the Post-Hoc LSD test.seemed to indicate a MZM1L-HA co-migration with the UQCRFS1-
containing intermediate, as a Rip1+Mzm1 complex is also observed by
2D analysis in yeast [14].
In order to test whether the UQCRFS1 and MZM1L-HA signal coinci-
dence in the low molecular weight protein complex by BNGE was only
due to co-migration in the gels or if it meant a physical interaction be-
tween both proteins, we performed co-immunoprecipitation assays. Im-
munoprecipitation from mitochondrial lysates, isolated from HeLa
cells overexpressing MZM1L-HA and using an anti-HA antibody,
also pulled down UQCRFS1, as it was speciﬁcally detected in the co-
immunoprecipitate. Conversely, when the immunoprecipitation assay
was performed using an anti-Rieske protein antibody, the HA signal cor-
responding to the tagged MZM1L protein was detected in the pulled-
down fraction, while it was absent in the control reaction using genericnthase activity (relative CIII/CS and relative CIV/CS activities) measured in the different
100-6.25%) of the total lentiviral particle production. The values plotted are the mean of
y signiﬁcant differences in the measured CIII/CS activities (p=0.018) while no differ-
differences (pb0.05) in the mean values between paired groups of data, according to
Fig. 5. Interaction between UQCRFS1 and MZM1L A) Denaturing second dimension anal-
ysis after the 1DBNGEof different transducedHeLa cell samples. Proteins in the blotswere
detected using the indicated speciﬁc antibodies. B) Co-immunoprecipitation analyses.
Proteins in mitochondrial lysates from transduced HeLa cells were immunoprecipitated
using the anti-HA antibody (left panel). The Western blots after SDS-PAGE were immuno-
detected using anti-Rieske protein and polyclonal anti-HA antibodies (Invitrogen). The
analysis indicated the presence of both proteins, UQCRFS1 and MZM1L-HA, in the
co-immunoprecipitation eluate. On the other hand, proteins in mitochondrial lysates
from transduced HeLa cells were immunoprecipitated using the anti-Rieske antibody,
and as a control for unspeciﬁc binding, generic mouse serum IgGs were used (right
panel). TheWestern blots after SDS-PAGEwere immunodetected using anti-HA antibody.
The analysis indicated the speciﬁc presence of MZM1L-HA in the same eluate when
UQCRFS1 was immunoprecipitated.
291E. Sánchez et al. / Biochimica et Biophysica Acta 1827 (2013) 285–293mouse IgGs (Fig. 5B). These data strongly support the existence of a
UQCRFS1+MZM1L-HA protein complex.3.5. MZM1L stabilizes UQCRFS1 in a step prior to the BCS1L-mediated
insertion into CIII
Most of the mitochondrial CIII deﬁciency (OMIM 124000) cases de-
scribed to date are due to mutations in the BCS1L gene (OMIM 603647).
BCS1L is a required factor for the correct biogenesis of CIII [29], as its de-
fects are correlated with low UQCRFS1 incorporation into the pre-CIII2
late intermediate [9,11]. MZM1L-HA was overexpressed in immortalized
skin ﬁbroblasts derived from Patients 1 and 2, which carry pathogenicBCS1Lmutations [9]. These cells showed lowUQCRFS1 amounts together
with the presence of UQCRC1 (Core 1)- and UQCRC2 (Core 2)-containing
subcomplexes, whichwere absent in the control samples [9]. MZM1L-HA
overexpression in these patient cells produced an increase in UQC
RFS1 steady-state levels (Fig. 6A). However, this increase was correlated
with the accumulation of the UQCRFS1 at the low molecular weight
intermediate/s rather than with a higher incorporation of the catalytic
subunit into CIII2 or an amelioration of the UQCRC1 assembly state
(Fig. 6B). These observations suggested that MZM1L bound to and was
able to stabilize UQCRFS1 in the case of its failed translocation to the
inner membrane due to BCS1L malfunction. This behavior of MZM1L is
consistent with a similar observation in yeast lacking the gene for BCS1
[14].
4. Discussion
Mitochondrial Complex III assembly in mammalian cells is not a
well-known process, as there is still a lack of information about how
the subunits are put together to give rise to the functional mature en-
zyme and what factors are involved in the assembly. In fact, up to
now the only two mammalian proteins known to play a role in CIII
biogenesis are BCS1L and TTC19, which were discovered by analyzing
human pathological cases associated with CIII deﬁciency [27,30]. The
yeast Saccharomyces cerevisiae is extremely useful as amodel organism to
study mitochondrial respiratory chain biogenesis thanks to the feasibility
of its genetic manipulation and its ability to grow on fermentable carbon
sources when the OXPHOS system is defective. Much of the knowledge
about the Complex IV assembly factors has been obtained by identifying
such proteins in yeast and then looking for the mammalian homologs
[31]. However, there are signiﬁcant differences between yeast and mam-
mals, especially in the peri-translational processes of the mitochondrially
encoded subunits where the proteins that exert these functions are not
exact orthologs, and new factors not related to the yeast proteins are
being discovered in human cells [32,33].
Complex III, or the cytochrome bc1 complex, is structurally very sim-
ilar between yeast and mammals, although the mammalian enzyme
contains an extra subunit, which is the cleaved UQCRFS1 (Rieske Fe–S
protein) pre-sequence that is retained as a structural part of the complex
[7]. A quite detailed assembly model has been described in yeast by
studying the subcomplexes formed in different deletion strains for
each of the structural subunits [34]. In addition, several factors assisting
the assembly process at different points have been identiﬁed [4]. The
best characterized factor is Bcs1, which translocates the catalytic protein
Rip1 (Rieske Fe–S protein) from the matrix to the mitochondrial inner
membrane in order to be inserted into a late core intermediate [8],
which is nearly the fully assembled complex, only lacking Rip1 and the
smallest accessory subunit Qcr10 (which is inserted after the catalytic
protein) [5]. The human counterpart of this essential assembly factor,
BCS1L, seems to perform the same function [9]. Another human protein,
TTC19, which does not appear to have a yeast homolog, is necessary for
the correct biogenesis of CIII, but its exact role in the process is yet to be
elucidated [30].
In this reportwe describe the identiﬁcation and characterization of a
new protein that we show to be involved in CIII assembly in human
cells, which is the Mzm1 homolog. Yeast Mzm1 has been recently de-
scribed to function in the late steps of bc1 complex assembly [12]. Func-
tional studies in yeast describe how Mzm1 is a LYR motif-containing
chaperone that stabilizes Rip1 prior to its inner membrane insertion
mediated by Bcs1, a function which is especially necessary at elevated
temperatures [13,14].
LYR motif-containing 7 (LYRM7) is a protein of the “Complex I LYR
family,”whosemain characteristic is theN-terminal LYRmotif important
for protein function and which includes members such as NDUFA6,
NDUFB9 (Complex I structural subunits) and the CII assembly factor
SDHAF1 [35], all of which are related to Fe–S cluster proteins. Our results
indicate that LYRM7 transcript variant 1, encoding a 104-amino acid
Fig. 6. Effects of MZM1L-HA overexpression in BCS1L mutated ﬁbroblasts. A) SDS-PAGE, Western Blot and immunodetection analyses, with the indicated antibodies, of two patient
(Pt) and two control (Ct) samples of immortalized ﬁbroblasts transduced with either empty vector or MZM1L-HA. B) 2D BNGE, Western blot and immunodetection analyses of the
immortalized ﬁbroblasts from Patient 1, which are compound heterozygotes of BCS1L mutations p.R73C and p.F368I [9], transduced either with the empty lentiviral vector or the
MZM1L-HA construct. Asterisks indicate unspeciﬁc signals obtained with the anti-Rieske protein antibody.
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UQCRFS1 in the mitochondrial matrix, for which we consider it the
human Mzm1 functional homolog or MZM1-like protein (MZM1L).
Several lines of evidence allow us to make this statement: First, ex-
pression of the human protein is able to restore respiratory growth in
yeast cells devoid of the endogenous Mzm1. This result indicates that
LYRM7/MZM1L possesses a homologous function, as it is able to compen-
sate for the bc1 complex defect induced by the lack of Mzm1, which is
mainly characterized by the loss of Rip1 [12,13]. Second, overexpression
of the protein increases UQCRFS1 steady-state levels in the BCS1L defec-
tive ﬁbroblasts. Third, high levels of MZM1L provoke the accumulation of
UQCRFS1 in a soluble mitochondrial fraction, in contrast to the situation
in which MZM1L levels are lower, where only a small proportion of the
subunit is soluble and most of it is tightly bound to the mitochondrial
inner membrane (Fig. 2C). This observation indicates than in the case of
MZM1L overexpression, most of the UQCRFS1, although not all, must be
located in the matrix together with the chaperone, making it more difﬁ-
cult for the subunit to reach the inner membrane. Lastly, MZM1L physi-
cally interacts with UQCRFS1, as demonstrated by their co-migration in
the Blue-Native gels and by their co-immunoprecipitation. UQCRFS1 is
mostly present in the MZM1L-HA-containing subcomplex when the lat-
ter is overexpressed, and this same subcomplex is also detected with
the anti-Rieske protein antibody in the control cells (transduced with
the empty vector) in much lower proportions (Figs. 3B and 5B).
Furthermore, high MZM1L-HA expression levels even produced a de-
crease in CIII activity in HeLa cells due to a reduced UQCRFS1 incorpora-
tion into CIII, as observed by the lighter signal detected for this subunit
in the BNGE,WBand immunodetections (Fig. 3A). The signalwas reduced
in an inverse proportion to theMZM1L-HA expression levels, and the im-
paired incorporation was more evident in the CIII2+CIV supercomplex
band. This ﬁnding is compatible with the observation by kinetic studies
and BNGE that the incorporation dynamics of UQCRFS1 were slower in
the CIII2+CIV and respirasome bands than in the isolated CIII2 band [36].
All the observations strongly suggest that UQCRFS1 stays retained in
the matrix and bound to MZM1L-HA within the low molecular weight
intermediate. One could argue that this result could be due to a domi-
nant negative effect because the addition of the HA tag is disturbing
the function of MZM1L. However, the addition of a C-terminal tag to
the yeast Mzm1 protein did not have any deleterious effect on its func-
tion, nor did the addition of a C-terminal tag to the human MZM1L
expressed in yeast [13] (Fig. 1B). In addition, by modulating theMZM1L-HA overexpression levels (lowering the virus titration while
infecting the cells), it was shown that the HeLa cells where MZM1L-HA
expression levelswere the lowest exhibited statistically signiﬁcant higher
CIII enzymatic activities, in comparison with the control cells and,
evidently, in comparisonwith the lineswith highMZM1L-HA expression.
This result suggests that the tagged protein, when expressed in the right
amounts, is able to cooperate with the endogenous factor to stabilize
UQCRFS1 for its incorporation into a mature CIII. This ﬁnding also indi-
cates that the right stoichiometry of the factor is necessary for its correct
function, as when there is an excessive amount of MZM1L, considerable
quantities of UQCRFS1 are retained in the wrong compartment, which
is counterproductive for correct CIII maturation. Accordingly, MZM1L-
HA overexpression was able to increase the low UQCRFS1 levels present
in BCS1L-mutated cells, but it could not ameliorate CIII assembly, as the
amount of UQCRFS1 incorporated into mature CIII2 remained low and
the accumulation of UQCRFS1 in the MZM1L-HA-overexpressing patient
cells occurred in the low molecular weight intermediate.
In conclusion, the results shown in this report allowus to introduce a
new player, MZM1L, in the last step of the mammalian CIII assembly
pathway, where pre-CIII is matured to become the functional enzyme
(Fig. 7). In addition, this study opens the possibility of screening for
pathogenicmutations in the LYRM7/MZM1L gene in yet unresolvedmi-
tochondrial disease cases associated with CIII deﬁciency. Additionally,
there is still muchwork needed to be done in order to identify the path-
way and additional factors taking part in the biogenesis of this mito-
chondrial respiratory chain central complex.
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